Amicus Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, FOLD, Amicus Therapeutics Inc, priceseries

Amicus Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
7.89
Close
7.89
High
8.11
Low
7.77
Previous Close
7.89
Daily Price Gain
0.00
YTD High
12.63
YTD High Date
Jan 5, 2022
YTD Low
7.60
YTD Low Date
Feb 24, 2022
YTD Price Change
-4.22
YTD Gain
-34.85%
52 Week High
12.63
52 Week High Date
Jan 5, 2022
52 Week Low
7.60
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-2.21
52 Week Gain
-21.88%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 27. 2017
6.43
Mar 7. 2017
7.04
6 Trading Days
9.49%
Link
LONG
Apr 19. 2017
7.18
May 3. 2017
7.56
10 Trading Days
5.24%
Link
LONG
Dec 20. 2017
13.50
Jan 8. 2018
14.49
11 Trading Days
7.35%
Link
LONG
May 14. 2018
14.24
May 23. 2018
15.38
7 Trading Days
8.01%
Link
LONG
Dec 31. 2018
9.58
Jan 22. 2019
11.75
14 Trading Days
22.67%
Link
LONG
Feb 22. 2019
11.75
Mar 19. 2019
13.47
17 Trading Days
14.64%
Link
LONG
Nov 7. 2019
8.92
Dec 5. 2019
10.27
19 Trading Days
15.14%
Link
LONG
Apr 16. 2020
10.61
Apr 30. 2020
11.93
10 Trading Days
12.45%
Link
LONG
Jun 16. 2020
13.07
Jul 13. 2020
15.16
18 Trading Days
15.97%
Link
LONG
Oct 9. 2020
15.12
Oct 30. 2020
17.94
15 Trading Days
18.72%
Link
LONG
Nov 3. 2020
18.97
Nov 19. 2020
21.76
12 Trading Days
14.72%
Link
LONG
May 28. 2021
9.26
Jun 16. 2021
10.08
12 Trading Days
8.91%
Link
LONG
Aug 4. 2021
9.68
Aug 18. 2021
10.27
10 Trading Days
6.05%
Link
LONG
Aug 20. 2021
10.54
Sep 10. 2021
11.15
14 Trading Days
5.76%
Link
LONG
Dec 17. 2021
10.84
Dec 31. 2021
11.61
9 Trading Days
7.09%
Link
Company Information
Stock Symbol
FOLD
Exchange
NasdaqGM
Company URL
http://www.amicusrx.com
Company Phone
(609) 662-2000
CEO
John Francis Crowley
Headquarters
New Jersey
Business Address
1 CEDAR BROOK DRIVE, CRANBURY, NJ 08512
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001178879
About

Amicus Therapeutics, Inc. is a biopharmaceutical company focuses on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for the treatment of rare diseases, pharmacological chaperones are a novel, first-in-class approach to treating a broad range of diseases, including lysosomal storage disorders and diseases of neurodegeneration. Amicus develops pharmacological chaperones oral therapies that bind to and stabilize the affected proteins, restoring their shape, proper trafficking, and biological activity. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Description

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading